Conexeu Sciences (NASDAQ: CNXU) has launched a human collagen program at its Vancouver research and development facility for regenerative aesthetics, starting with the production of its first pilot batch of human type I collagen.
According to Conexeu, demand for tissue restoration is rising with aging and with GLP-1 weight loss. The GLP-1 drug market was estimated at roughly $79 billion in 2025 and is projected to reach about $190 billion by 2035, and aesthetic provider revenue tied to GLP-1 weight loss is projected to grow from about $0.7 billion in 2025 to $2.0 billion by 2030.
In a statement, Miles Harrison, president and CEO of Conexeu, commented, “GLP-1 has created a new patient profile: people whose bodies have changed faster than today’s aesthetic injectables were built to address, and restoring that tissue takes more than volume. Human collagen is an important ingredient, but on its own it does not recreate the complexity of native extracellular matrix. We believe the patented CXU formula provides a broader ECM framework than collagen alone and may offer a differentiated scaffold-based approach to aesthetics, based on more than a decade of university research and more than two years of development at Conexeu. That is why we believe we are well positioned to bring human collagen into aesthetics.”
